Chemotherapy of advanced renal adenocarcinoma

Alden G. Cockburn, Ralph W deVere White

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The treatment of advanced renal cell carcinoma is a continuing problem because of the lack of effective systenic therapy. A review of recent clinical trials of various chemotherapeutic agents reveals vinblastine, CCNU, and Methyl GAG to be the most effective of all agents tested. This efficacy however, is in the modest range of 15% partial response. Somewhat increased efficacy is seen in combination regimens containing vinblastine. Hormonal therapy with progestins and androgens is widely used because of their slight efficacy, lack of toxicity, and the psychological benefit of doing something. It should be considered, when judging the efficacy of any systemic therapy used in this disease, that the patients with minimal pulmonary disease always fair the best.

Original languageEnglish (US)
Pages (from-to)136-141
Number of pages6
JournalWorld Journal of Urology
Issue number2
StatePublished - Jul 1984
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Chemotherapy of advanced renal adenocarcinoma'. Together they form a unique fingerprint.

Cite this